Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma

Condition:   High-risk Neuroblastoma Interventions:   Drug: Dinutuximab Beta;   Drug: 13 cis retinoic acid Sponsor:   BeiGene Not yet recruiting

Source: ClinicalTrials.gov - May 13, 2022 Category: Research Source Type: clinical trials